Clinical Trial Update: Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO [Phase 2]

View source ↗

Summary

Phase 2 trial of dacomitinib in advanced non-small cell lung cancer evaluating prophylactic interventions for dermatologic and gastrointestinal adverse events, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Dacomitinib (dacomitinib)

Snippet

Sponsor: Pfizer | Conditions: Non Small Cell Lung Cancer (NSCLC) | Phase 2 | Status: COMPLETED | Results posted: 2016-08-17